Key Findings
A critical review published in the IJPS Journal thoroughly scrutinizes the current state of nanotechnology in drug delivery and the pragmatic challenges impeding its commercialization and clinical translation. The most salient point highlighted is the persistently low percentage of nanoparticles that actually reach their intended tumor targets within the body. This inefficiency raises concerns about limited therapeutic efficacy and underscores an urgent need for the development of superior drug loading technologies and intelligent release systems.
Technical and Clinical Details
Previous research has consistently shown that many nanoparticles are cleared from circulation by the reticuloendothelial system (RES) or degraded before reaching their tumor sites. Consequently, the delivery efficiency to target tissues typically remains below 1%, severely limiting their practical utility as drug delivery systems. The article argues that overcoming this challenge necessitates advancements in nanoparticle surface modification (e.g., PEGylation for stealth effects) and the development of novel mechanisms to enhance intracellular delivery.
Furthermore, the review points out that improving drug loading capacity and developing “smart release systems” that respond to specific stimuli within the body (such as pH, temperature, or enzyme concentrations) are crucial for increasing the efficiency of nanotechnology-based drug delivery. It also critically emphasizes that preclinical animal models often fail to adequately replicate the complex human biological environment, making the establishment of more physiologically relevant in vitro and in vivo testing models indispensable for developing truly effective nanotherapeutics.
Background and Industry Context
Nanotechnology has garnered significant expectations as a transformative tool for achieving personalized and precision medicine. It was believed to hold immense potential for enhancing drug targeting specificity and reducing side effects, particularly in cancer and gene therapy. However, despite early enthusiasm, the number of nanotherapeutics successfully advancing through clinical stages remains limited. This article vividly exposes the practical gaps faced by the industry and strongly advocates for bridging the divide between fundamental research and clinical application.
Strategic Significance and Outlook
This review suggests that the field of nanotechnology in drug delivery must adopt a more rigorous scientific approach and a pragmatic perspective. Going forward, researchers and companies must not only focus on developing novel nanomaterials but also thoroughly validate their in vivo behavior, target delivery efficiency, drug release control, and, most critically, their efficacy and safety in human clinical settings. By adhering to these principles, truly innovative nanotherapeutics can be brought to patients, maximizing the full potential of nanomedicine and ensuring its tangible contribution to healthcare.
Source: #
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments